A Special Tribute
Baruch S. Blumberg
July 28, 1925 – April 5, 2011
Dear Friends,

This year has been both a time of celebration and reflection for the Hepatitis B Foundation. We celebrated our 20th anniversary as the only national nonprofit organization solely dedicated to finding a cure for hepatitis B and improving the quality of life for those affected worldwide.

We also reflected on the loss of a great scientist and our good friend and co-founder, Baruch S. Blumberg, who won the Nobel Prize for his discovery of the hepatitis B virus. This has literally saved hundreds of millions of lives through the invention of the first “anti-cancer” vaccine, the hepatitis B vaccine.

In 2011, we launched bold new initiatives to help increase the momentum around hepatitis B. This includes the Haimen City Project that is educating one million residents in China; the Hep B Free Philadelphia citywide coalition with 60 partner organizations to reach at-risk communities; and our Natural Products Discovery Institute that was established to advance drug discovery through the priceless natural products collection that was donated to us by Merck & Co.

We continue to be an essential source of scientific innovation and public health commitment even after 20 years. And we thank all of our many friends who have contributed time, talent and donations to ensure our success!

With appreciation,

Timothy M. Block, Ph.D.
President and Co-Founder

Joel D. Rosen, Esq.
Chairman of the Board

Our Mission

The Hepatitis B Foundation is a national nonprofit organization dedicated to finding a cure and improving the quality of life for those affected by hepatitis B worldwide through research, education, and patient advocacy.
Baruch S. Blumberg, MD, PhD
July 28, 1925 – April 5, 2011

A Special Tribute
By W. Thomas London, MD, HBF Board Director and Senior Medical Advisor

“I first met Barry Blumberg in July 1962 at the National Institutes of Health in Bethesda, MD.”

Barry was then 36 years old and had already authored or co-authored about 50 papers. Scientifically, Barry was a throwback to the naturalists of the 19th century, like Charles Darwin and Alfred Russell Wallace. He actually modeled his life on theirs.

In 1964, Barry was recruited to become the head of a new Division of Clinical Research for the Institute for Cancer Research (precursor to the Fox Chase Cancer Center in Philadelphia, PA). Soon after I arrived in 1966, Barry persuaded Alton Sutnick, Betty Jane Gerstley and me to focus our efforts on understanding the biological significance of Australia antigen. We found that Australia antigen was closely associated with one form of viral hepatitis, later called hepatitis B.

At the same time, Barry, in collaboration with Manfred Bayer, found that the Australia antigen was a particle similar in appearance to a virus. That was enough information for Barry to hire Irving Millman from Merck and begin to develop a vaccine. By 1975, before the vaccine had even been tried in humans, Barry predicted in print that the vaccine would not only prevent infection with the hepatitis B virus but that it would also prevent liver cancer. Therefore, it would be the first cancer vaccine.

In 1976, Barry was awarded the Nobel Prize in Physiology or Medicine for his new approach to identifying an infectious agent. Barry made his success a celebration for everyone in our group. He took as many of us to the Nobel Prize ceremony as he was permitted. The trip to Stockholm will always remain etched in my memory as a time when we all shared an experience that could never be matched.

Barry was always a happy person. He celebrated his own life by living it to the fullest. He was always a participator, never a spectator. He ran, hiked, climbed mountains, kayaked, canoed and traveled to the four corners of the earth. As he hit succeeding milestone birthdays, my wife, Linda, and I would say Barry is the happiest 75 year old we knew, the happiest 80 year old we knew and finally the happiest 85 year old we knew.

I believe that Barry died a happy, contented man. He left a legacy of accomplishments that saved an enormous number of lives and prevented hundreds of millions of people from becoming ill with the hepatitis B virus.

For Barry, the world was his laboratory and playground. The world has responded by making July 28th, his birthday, World Hepatitis Day. But his enduring gift to me was his 49 years of friendship.


“Anyone who has been immersed in the world of a busy city hospital, a world of wretched lives, of hope destroyed by devastating illness, cannot easily forget that the objective of big-medical research is, in the end, the prevention and cure of disease,” said Dr. Blumberg in his autobiography for The Nobel Prize.
HBF Receives Priceless Natural Products Collection

The HBF and its research affiliate, the Institute for Hepatitis and Virus Research (IHVR), received as a donation the priceless Natural Products Library and the Schering-Plough Legacy Culture Collection from Merck & Co. in June 2011. It is considered one of the largest, most diverse, and best curated natural products collection in the world. Now housed in the Natural Products Discovery Institute (NPDI), a division within the IHVR, the collection will be open to researchers around the world to benefit humankind. With almost 50% of all medications in use today having their origins in natural products, the collection is expected to provide unparalleled drug discovery opportunities.

Princeton Workshop: Are New HBV Drugs Needed?

The prestigious Princeton Workshop was held at the HBF headquarters in Doylestown, PA for the first time in honor of its 20th Anniversary celebration. A small group of the nation’s thought leaders were invited to discuss the current state of hepatitis B therapy. The 23 attendees agreed that new drugs targeting all stages of the HBV life cycle are needed that will not require lifetime use. Started in 1995, the Princeton Workshop invites leading scientists from academia, industry and government to promote high-level scientific exchange and collaborations dedicated to hepatitis B.

Our Research Highlights

- **Merck & Co. donated its entire Natural Products Library** to the HBF’s research institute that provides access to a treasure trove for potential new therapies

- **HBF 079** is a new compound identified as highly active against liver cancer in tissue culture and animals *(A Cuconati)*

- **HBF 359**, an experimental inhibitor of HBsAg in tissue culture, has been funded for further development with a $3 million NIH grant *(A Cuconati, M Xu)*

- **HBV assembly dependent replication inhibitors** are a family of compounds that could be a new category of treatment for hepatitis B *(JT Guo)*
25th Anniversary of the International HBV Meeting

The 25th Anniversary of the International HBV Meeting was held in October 2010 for the first time in Asia – Taipei, Taiwan. Coordinated by the HBF since 2005, almost 300 scientists from around the world attend the meeting, which continues to be the only scientific conference dedicated to the molecular biology of hepatitis B and hepatitis D.

HBV Meeting co-chairs Drs. PJ Chen (right) and Adam Zlotnick receive HBF ties. (October 2010)

Mentoring the Next Generation of Scientists

As a world-class research center, the HBF and its research institute are committed to attracting top talent to the field of hepatitis B and liver cancer research. This year, we “graduated” 17 college and high school students who worked with our scientists on different projects. The program is funded in part by the PA Department of Health, Merck’s West Point Charitable Contributions Committee, Universal Health Systems, Univest Bank and Walmart.

2011 Summer college interns.

2011 Bruce Witte Lecturer

Internationally renowned medical researcher Adrian Di Bisceglie, MD, chief of Hepatology at Saint Louis University School of Medicine, delivered the 10th Annual Distinguished Bruce Witte Lecture on “Management of Hepatocellular Carcinoma” to a full audience. The Bruce Witte Lectures were established by HBF co-founders Paul and Janine Witte in memory of Paul’s son.

Witte Lecturer – Dr. DiBisceglie. (May 2011)

Our Research Highlights

- Interferon (IFN) eliminates all detectable cccDNA in culture, which represents the potential for targeting covalently closed circular DNA (cccDNA), which most scientists believe must be eliminated for a cure (JT Guo, H Guo, A Cuconati)

- Our GP73 biomarker of HCC is now available for use in China

- Major US diagnostic company executes its license to develop our HCC biomarker in the U.S. (T Block, A Mehta)
  Yes, these are the same markers being sold in China!
[OUTREACH] GATEWAY TO CARE

A TALE OF TWO CITIES

The HBF launched its Gateway to Care public health program with the goal of creating two demonstration projects in Philadelphia and Haimen City, China. We started the Philadelphia project in 2008 and it has successfully developed into a full-fledged community-based coalition.

This year on April 8, 2011, we officially launched the Haimen City Project in China, which was made possible by a $400,000 educational grant from the Bristol-Myers Squibb Foundation. The program in China is a multi-year, citywide initiative that will raise awareness about hepatitis B among its one million residents, educate thousands of health care providers to improve screening and management of hepatitis B, and conduct research to decrease the risk of infected pregnant women transmitting the virus to their newborn babies at birth. The primary goal of the campaign is to create a model program that can be readily adapted and duplicated in other cities to help reduce the enormous burden of hepatitis B in China.

Hep B Free Philadelphia Mobs City Hall!

The HBF’s Gateway to Care program in Philadelphia has evolved into the dynamic Hep B Free Philadelphia campaign which is a community-based coalition of 60 partners. This year we organized the first ever B A Hero Flash Mob at Philadelphia’s City Hall during May Hepatitis Awareness Month to attract attention to our campaign. The volunteer energy of more than 100 medical, public health and college students power the citywide awareness, education and screening events.
HBF Invited to the White House

World Hepatitis Day was officially recognized in 2011 by the World Health Organization to be July 28, the birth date of Dr. Baruch Blumberg who discovered the hepatitis B virus. To commemorate this day, the White House hosted a special briefing on viral hepatitis where President Obama’s Presidential Proclamation was read. The HBF was proud to be invited to this historic event.

HHS Action Plan for Combating Viral Hepatitis

The U.S. Department of Health and Human Services (HHS) issued its first National Action Plan for Viral Hepatitis. The Plan, created by an interagency work group assembled last year by Dr. Howard Koh, Assistant Secretary for HHS, sets priorities in six critical areas with the goal of improving hepatitis prevention and care at the federal, state, and local levels.

Milestones in Our History

1965 Dr. Baruch Blumberg discovers the hepatitis B virus
1969 Dr. Blumberg invents the first HBV vaccine
1971 Blood banks use his HBV blood test to screen donors
1976 Dr. Blumberg wins the Nobel Prize for his discovery of hepatitis B virus
1981 First commercial HBV vaccine approved in the U.S.
1986 Recombinant HBV vaccine approved that is now used worldwide
1991 New Hope for Hepatitis B
The Hepatitis B Foundation established as a 501(c)3 nonprofit organization in New Hope, PA by founders Timothy and Joan Block, and Paul and Janine Witte.
1992 A Nobel Beginning
Nobel Laureate Dr. Baruch Blumberg lends his personal and professional support to the Hepatitis B Foundation.
1994 First HBF Lab
Dr. Joseph Gonnella, dean of Jefferson Medical College in Philadelphia, designates the first HBF lab.
In Gratitude

Our Donor Honor Roll

From our earliest days, the Hepatitis B Foundation has been supported by generous individual donations, grants, workplace and matching gifts, in-kind donations, donations of auction items and sponsorships for our Crystal Ball, and attendance at our special events. We are grateful to every individual and organization that has stepped forward to advance our Cause for a Cure. Thank you!

DONATIONS: JULY 1, 2010 – JUNE 30, 2011

Ambassadors’ Circle
$500 - $999
Clement Au
Eileen Beck
Tom Block
Alan Brownstein
Andrew Chen
Michael Christenson
Tacie Dejanikus
Joshua and Miriam Feldstein
Julie Jacob
Joanne Jensen
Emmet Keeffe
Anna Lee
Jean Miller
James Mongold
Janice Morris
Deborah Nelson
Timothy Peissig
Yusheng Qu
Shawn Ridilla
Mark and Lori Rosolowsky
Y. Clement Shek
Ying-Hsiu Su
Michael Wehner
Stephen Wong

Discovery Circle
$250 - $499
Joe Benning and Maryann McDonald
Barbara Allar
Det and Bridget Ansinn
Earl Bierman
Joanne Blasenheim
Randee Block and David Visinger
Robert Britt
Isaac Broberg
Paul and Chari Cohen
Lawrence Converso
Ronald Drakeford
Curt and Roseanne Friehs
Joseph Gonzella
David Hines
Wilson Py Hong
David Huang
Donald and Kim Jungkind
Fred Klaessig
R. Donald Leedy
Frank and Linda Lippow
Tulin Morcol
Catherine Ng
Pam Norton and Joe Potz
Andrea Polesky
Daniel Smith
Eric Stollnitz
William and Irene Taylor
Eva Tsai
Sharon Victor
Debbie Wagner

Outreach Circle
$100 - $249
Ishola Adeyemo
Susan Bellaire
Patricia Benham
Baruch Blumberg
Greg Burch
Kevin Burkholtser
Jose Mari Casas
Garrett Chang
Moon Chen
Ricky Choi
Warren Chu
Marc and Ann Clearfield
Joe and Molli Conti
Cheryl Corley
Suzanne Crilley
William Cumby
James and Carol Curry
Kathy Czupich
Matt Damon
Ciro D’Angelo
Michael Dean
Se Jong Ding
William Donaldson
Arnold Doyle
Kathy Dunaway-Knight
Vicki Sheir Dunn
John Evans
Brian Free
Lawrence Friedman
Jay W. and Linda Funck
Roger Gallic

President’s Circle
$1,000 - $2,499
Stanley and Gerri Broadbent
Faith Calhoun
The Esterly Family Fund of The Pittsburgh Foundation
Matt and Anne Greene
David and Cynthia Gruber
Terry Kaplan
Amy Ko-Tang
Anand and Valerie Mehta
John Pramod
Gurney Sloan
Bud and Patricia Tennant
The Tulchin Family Foundation
Robert Zivin

BENEFACTORS’ SOCIETY
$1,000 - $10,000 and more

Visionary Circle
$10,000 and more
Timothy and Joan Block
Kahn Charitable Foundation

Global Circle
$5,000 - $9,999
Gunst Charitable Foundation

Founders’ Circle
$2,500 - $4,900
David Crane
Joel Rosen
W. Thomas and Linda London

Founders’ Circle
$1,000 - $2,499
Stanley and Gerri Broadbent
Faith Calhoun
The Esterly Family Fund of The Pittsburgh Foundation
Matt and Anne Greene
David and Cynthia Gruber
Terry Kaplan
Amy Ko-Tang
Anand and Valerie Mehta
John Pramod
Gurney Sloan
Bud and Patricia Tennant
The Tulchin Family Foundation
Robert Zivin

1995
All-Star Scientists
HBF convenes first Princeton Workshop of thought leaders from academia, government and industry to discuss new HBV therapeutic strategies.

1996
Opening the Doors
HBF rents first office, hires first employee, and launches www.hepb.org

1999
Traveling the State
PA Department of Health provides first major grant to HBF to conduct statewide hepatitis training programs.

2000
Bruce Witte Remembered
HBF co-founders Paul and Janine Witte establish the Bruce Witte Scholarship and Lecture Series in honor of Paul’s son.
DONATIONS : JULY 1, 2010 – JUNE 30, 2011 (Continued)

Outreach Circle
$100 - $249
Khamvialy Gebretensi
Sinnathamby
Gomathinayagam
Robert Gottfried
Douglas Green
Charles and Donna
Grezlak
Edward Griffith
Richard Haliburton
Dorothy Harris
Carol Hart
Anne Heacock
Peter Hoekstra
Jun Iwata
Bonnie Jung
Barry Kahn
Alan Keim
Robert Kelley
Kelvin Khoo
Albert Ku
Kathryn Kucera
Michael Landis
Karen Lasorda
Donna Lazorik
Anh Tuyet Le
Teng Ni Leaw
Joanna Lee
Yim Leung
Jack Lyle
Scott and Darryl
Mackeverican
Gerard Marini
Bruce Maryanoff
Brian McMahon
Shanti Mehta
Robert Michaud
Jennifer Miller
Catherine Morris
Richard Moyer
Estrella Munoz
Joseph Paquiligian
Edward Peritz
Janet Perper
Dung Pham
Brian Quigley
Paul Raetsch
Wen X. Zeng Raiti

Awareness Circle
Up to $99
David Rolf
Richard and Priscilla
Rosenberger
William Royal
James Ryan
Ronald and Joyce
Sanderson
Richard Senker
John and Susan Shelly
James and Erica Shrimp
Ronald Sicilia
Michael Sidor
Clint Smith
Ayotunde Sodipe
Harriet Stenzel
Herbert Stevens
Ephraim Sudit
John Sweeney
James Talamonti
Judy Tam
Joly Tang
Marcia Taylor
Christine Tran
C. Theodore Tucker
Nithya Vijayavel
Thien Vuong
Elizabeth Walsh
Lan Wang
Dietmar Weselin
Deborah Wexler
Thomas Wight
Roy Williams
Shari Winkler
Helen Wise
George and Cathleen
Woods
Feng Xie
Hong Xin
Michael Xu
Mary Yee
Ellen Lam Yeh
Zongqiang Yu
Michael Zammit
Mingyu Zhu

David Harper
Hunt Hawkins
Harry and Dorothy
Hellerman
Hsiu-Zu Ho
Henry Ho
Xiaolong Hong
Alfred How
Paing Huang
Nina Ignaczak
Cara Jobson
Fnu Kamlesh
Ayan Karabudak
Nina Katz
Barry Klieger
Archie Kwan
Mark Chengchun Lee
King Liang
Michael Line
Erica Litschi
Rosie Ly
Marlene Madinecea
Patricia Maness
Karen Mera
Robert Mickle
John Miller
Edith Mock
Diane Moloney
Thuan Nguyen
Mark Obermann
Kemlayefa Olue
Donald Page
John Perez
Cari Peridier
Anja Perovic
James and Diane Price
David Provenzano
Robert Radenbaugh
Rita Shiue
Manu Shrivastava
Cui Shuo
Denise Stern
Jeanne Stern
Roger J. Sun
Jonathan Tan
Janet Tangney
Nancy Tolle
Patricia Trainor
Hin Wing Tse

Corporate and Foundation
Donations
Abbott Laboratories
Bayer HealthCare
Bristol-Myers Squibb
Bristol-Myers Squibb Foundation
Gilead Sciences
GlaxoSmithKline
Merck & Co.
Merck West Point Charitable
Contributions Committee
Onyx Pharmaceuticals
UHS of Delaware, Inc.
Univest Bank

Additional Donations and
Matching Gifts
AAPCHO
Bank of America Matching Gifts
Fiberline
Fox Chase Cancer Center
Genentech Givingstation
Gold Social Gerstein LLC
GoodSearch
Home Health & Hospice Care, Inc.
Infectious Awareables
Liberty Mutual Foundation Match

Federal and State Grants
National Institutes of Health
PA Department of Health

2001 Gathering of Friends
HBF hosts the first national Patient Conference in Doylestown, PA.

2002 Future Scientists of America
HBF establishes Summer Research Internship program to train college students and receives $400,000 NIH grant to expand www.hepb.org.

2003 Pennsylvania Steps Up
HBF, with Delaware Valley College, receives a $7.9 million grant from Pennsylvania to build a biotech center.

2004 New Partnerships
HBF forms new academic partnerships with Drexel University and the University of Oxford. Also creates a research affiliate, the Institute for Hepatitis and Virus Research.
The Hepatitis B Foundation started as a kitchen grassroots effort and today it is the global authority dedicated to eliminating hepatitis B worldwide.

Crystal Ball: Celebrating 20 Years!

The Hepatitis B Foundation (HBF) celebrated its 20th Anniversary with hundreds of community and business leaders attending the Crystal Ball. A record-breaking $95,000 was raised at its signature fundraising event. A special video was shown that included the last interview with Nobel Laureate Dr. Baruch Blumberg who was one of the co-founders of the HBF. All proceeds of the gala are used to fund the HBF’s valuable research, outreach and advocacy programs.

2005
National Advocacy Successes
First National Hepatitis B Act is introduced in Congress by Reps. Charlie Dent (PA) and Mike Honda (CA); first Congressional Briefing on Hepatitis B and first National Hepatitis B Awareness Week Congressional resolution.

2006
Building for Discovery
HBF establishes the Pennsylvania Biotechnology Center, which is owned in partnership with Delaware Valley College, to accelerate its research mission.

2007
An International Focus
HBF asked to become the official sponsor of the annual International HBV Meeting; begins Scientists Without Borders, an international research exchange program.

2008
Gateway To Care
HBF initiates the Gateway to Care public health program in Philadelphia to increase awareness, screening and linkage to care in high-risk Asian communities.
**Source of Funds** - HBF & IHVR Combined
(Total $4,662,708)

- **Grants** 81%
  - $3,791,343
- **Charitable Contributions** 12%
  - $549,103
- **Interest** <1%
  - $3,690
- **Other** 7%
  - $318,572

**Uses of Funds** - HBF & IHVR Combined
(Total $4,776,664)

- **Direct Research** 57%
  - $2,719,762
- **Outreach and Education** 17%
  - $799,018
- **Public Health** 6%
  - $298,471
- **General and Administrative** 13%
  - $619,929
- **Depreciation** 3%
  - $139,119
- **Development** <1%
  - $28,264

* The summarized financial information is excerpted from financial statements audited by EisnerAmper LLP, which are available upon request.

---

**2009**
**Research Breakthrough**
Early detection biomarkers for fibrosis and liver cancer discovered and are optioned by major U.S. diagnostics company.

**2010**
**Making An Impact**
HBF publishes the first national recommendations for the care and treatment of children living with hepatitis B; helps organize the first World Hepatitis Day Rally in Washington, DC; and serves on the committee of the first Institute of Medicine report on Hepatitis and Liver Cancer.

**2011**
**Global Spotlight**
HBF celebrates 20 years and launches Gateway to Care program in Haimen City, China and becomes a charter member of the International Coalition to Eliminate Viral Hepatitis in Asia-Pacific (CEVHAP).
Hepatitis B is an enormous global health problem.

- 2 billion people worldwide have been infected by hepatitis B. (1 out of every 3)
- 1 million people in the world die from hepatitis B each year.

Hepatitis B causes 80% of primary liver cancer worldwide.

- Liver cancer is the 3rd leading cause of death in the world.
- In the U.S., liver cancer rates are increasing as most other types of cancer are decreasing.
- The hepatitis B vaccine is the 1st anti-cancer vaccine — by preventing a hepatitis B infection.

There is no known cure for more than 400 million people worldwide living with hepatitis B.

- Hepatitis B is preventable and treatable — now let’s make it curable!

Learn more about hepatitis B and the important work of the Hepatitis B Foundation by visiting www.hepb.org.